Justin Ferdinandus

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

Michael S. Hofman, John Violet, Rodney J. Hicks et al. · The Lancet Oncology · 2018 · 1.1K citations

Dosimetry of ¹⁷⁷Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes

John Violet, Price Jackson, Justin Ferdinandus et al. · Journal of Nuclear Medicine · 2018 · 454 citations · Full text

Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of ¹⁷⁷Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer

John Violet, Shahneen Sandhu, Amir Iravani et al. · Journal of Nuclear Medicine · 2019 · 269 citations · Full text

Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617

Justin Ferdinandus, John Violet, Shahneen Sandhu et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2020 · 147 citations

Biomarker (Medicine), Prognostic Biomarkers, Urology +6

Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities

Wolfgang P. Fendler, Kim M. Pabst, Lukas Kessler et al. · Clinical Cancer Research · 2022 · 127 citations · Full text